Immune cell therapy targets belly fluid in ovarian cancer

NCT ID NCT07435701

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment for advanced ovarian cancer patients who have a lot of fluid in their belly (ascites) and have not responded to standard therapies. The treatment involves injecting special immune cells called SK-NK cells directly into the abdomen once a week for four weeks. The goal is to see if it is safe and can reduce the need for fluid drainage. The trial is small, with 29 participants, and is in early phases to find the right dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SK-NK cells (a type of immune cell from a donor, given into the belly)
What this could lead to: If it works, this could offer a new way to control severe fluid buildup and slow tumor growth in advanced ovarian cancer patients who have run out of standard options.
What could go wrong: This is a very early, small trial (29 people) testing safety and dosing first. It may not work, and there are risks like allergic reactions or side effects from the cell infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASCITES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ascites ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASCITES OVARIAN NEOPLASMS MALIGNANT

Contacts and locations

Show contact details

Locations

Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.